Cardiology: Treatment of Heart Failure

DTMU
Treatment of Heart failure: From
symptomatic to disease modifying
therapy
Cardiology
Vedica Sethi
5/1/2020

May 1, 2020
[TREATMENT OF HEART FAILURE: FROM SYMPTOMATIC
TO DISEASE MODIFYING THERAPY]
2
Table of Contents:
1. Abstract
2. What is Heart Failure?
3. Treatment of Heart Failure
(i) Basic Overview of Drugs used in Heart Failure
(ii) Pharmacological therapy: Primary Drugs
(iii) Pharmacological therapy: Secondary Drugs
(iv) Non-Pharmacological Treatment
(v) Devices and Heart Transplant
(vi) Recommended Algorithm
4. Conclusion
5. References

May 1, 2020
3
1. Abstract
Heart Failure (HF) is the most widely recognized cardiovascular disorder behind medical
clinic affirmation for individuals more established than 60 years old. Hardly any regions in
medication have advanced as surprisingly as HF treatment in the course of recent decades.
Be that as it may, progress has been reliable just for ceaseless HF with diminished
discharge part. In intensely decompensated HF and HF with safeguarded discharge part,
none of the medications tried to date have been conclusively demonstrated to improve
endurance. Deferring or forestalling HF has gotten progressively significant in patients who
are inclined to HF. The anticipation of declining interminable HF and hospitalisations for
intense decompensation is likewise critical. The target of this paper is to give a compact
and down to earth rundown of the accessible medication medicines for HF. The most ideal
proof based medication treatment (counting inhibitors of the renin–angiotensin–
aldosterone framework and β blockers) is helpful just when ideally actualized.
Notwithstanding, usage may be testing. To accept that ailment the executives projects can
be useful in giving a multidisciplinary, comprehensive way to deal with the conveyance of
ideal clinical consideration.
Keywords; heart failure, multidisciplinary approach, Beat-blocker, RAAS framework

May 1, 2020
4
2. What is Heart Failure (HF)?
HF, otherwise called congestive cardiac failure (CHF), is the point at which the heart can't
siphon adequately to keep up blood stream to meet the body's needs.(1)(2)(3) Signs and
side effects of HF generally incorporate shortness of breath, tiredness, and edema. The
shortness of breath is normally more awful with exercise or while resting, and may wake
the individual at night. A constrained capacity to exercise is additionally a typical feature.
Chest discomfort, including angina, doesn't regularly happen because of heart failure.(4
)
Regular reasons for HF incorporate coronary artery disease, including a past myocardial
dead tissue (respiratory failure), hypertension, atrial fibrillation, valvular coronary illness,
alcohol abuse, infection, and cardiomyopathy of an obscure cause. These reasons for HF by
changing either the structure or the capacity of the heart.(5
)
The two sorts of left ventricular cardiovascular failure –HF with reduced ejection fraction
(HFrEF), and HF with preserved ejection fraction (HFpEF) – depend on whether the capacity
of the left ventricle to contract, or to unwind, is affected. The seriousness of the HF is
1
“Dorlands Medical Dictionary.”
2
“Heart Failure - Symptoms and Causes.”
3
“Definition of Heart Failure.”
4
“Management of Acute Decompensated Heart Failure - Google Books.”
5
“Oxford Textbook of Heart Failure - Roy S. Gardner, Andrew L. Clark, Henry Dargie - Google Books.”

May 1, 2020
5
reviewed by the seriousness of manifestations with exercise.(6
) Myocardial infarction (MI)
isn't equivalent to HF (in which part of the heart muscle dies) or cardiac arrest (in which
blood stream stops altogether).( Other illnesses that may have indications of HF
incorporate obesity , kidney failur, liver failure, iron deficiency, and thyroid disease.(7
)
Diagnosis depends on side effects, physical discoveries, and echocardiography. Blood
tests, electrocardiography, and chest radiography might be helpful to decide the hidden
cause.(
Treatment relies upon the seriousness and reason for the disease. In individuals with
constant deterioration of heart condition, treatment usually comprises of way of lifestyle
changes, for example, quit smoking, physical exercise, and dietary changes, just as
medications. In those with HF because of left ventricular failure, angiotensin changing over
chemical inhibitors, angiotensin receptor blockers, or valsartan/sacubitril alongside beta
blockers are recommended. For those with extreme illness, aldosterone antagonists, or
hydralazine with a nitrate might be used. Diuretics are valuable for forestalling diuresis
maintenance and the subsequent shortness of breath.(8
) Sometimes, contingent upon the
reason, an embedded gadget, for example, a pacemaker or an implantable heart
defibrillator (ICD) might be recommended. In some moderate or serious cases, heart
resynchronization treatment (CRT) or cardiovascular contractility modulation might be of
benefit. (9
) A ventricular assist device (for the left, right, or the two ventricles), or
sporadically a heart transplant might be suggested in those with extreme ailment that
endures regardless of all other measures.(10
)
HF is a typical, expensive, and conceivably lethal condition. In 2015, it influenced around 40
million individuals globally. Overall around 2% of grown-ups have heart failure and in
those beyond 65 6 years old, increments to 6–10%. Rates are anticipated to increase. The
danger of death is about 35% the primary year after determination, while constantly year
the danger of death is under 10% for the individuals who remain alive. This level of danger
of death is like some cancers. In the United Kingdom, the malady is the explanation behind
6
“Exercise‐based Cardiac Rehabilitation for Adults with Heart Failure.”
7
National Clinical Guideline Centre (UK), Chronic Heart Failure.
8
WRITING COMMITTEE MEMBERS et al., “2016 ACC/AHA/HFSA Focused Update on New Pharmacological
Therapy for Heart Failure.”
9
Tracy et al., “2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of
Cardiac Rhythm Abnormalities.”
10
Kuck et al., “New Devices in Heart Failure.”

May 1, 2020
6
5% of crisis clinic admissions. HF has been known since old occasions, with the Ebers
papyrus remarking on it around 1550 BCE.(11
)(12
)
3. Treatment of Heart Failure
(13
)
A few enormous clinical preliminaries led over the previous decade have indicated that
pharmacologic interventions can drastically diminish the grimness and mortality related
with HF. These preliminaries have changed and improved the restorative worldview for HF
and expanded treatment objectives past restricting congestive side effects of volume over-
load.
(i) Basic overview of Drugs used in Heart failure
11
Dickstein et al., “ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
2008.”
12
Metra and Teerlink, “Heart Failure.”
13
Trevor, Katzung, and Kruidering-Hall, “Drugs Used in Heart Failure.”

May 1, 2020
7
(14
)
14
Trevor, Katzung, and Kruidering-Hall.

May 1, 2020
8
(15
)
15
Trevor, Katzung, and Kruidering-Hall.

May 1, 2020
9
(i) Pharmacological therapy: Primary Drugs
a) ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEi)
ACEi are shown in the treatment of all patients with systolic HF. Various milestone
randomized, controlled trials 6–8 have exhibited the viability of these medications in
lessening mortality in asymptomatic and indicative patients.(16
)
On account of apparent dangers and contraindications, ACE inhibitors are frequently
avoided in patients with HF. Renal dysfunction and cough are viewed as absolute
contraindications. At the point when the systolic circulatory strain is under 100 mm Hg (17
)
or the creatinine level is raised, cautious observing is justified during the commencement
of ACE inhibitor treatment.
The dosing of ACE inhibitors is disputable. The Assessment of Treatment with Lisinopril
and Survival (ATLAS) Study tried to investigate whether higher doses of ACE inhibitors
would be progressively compelling.(18
) In any case, the ATLAS study contrasted high
measurements with low doses, and there was no correlation with the objective doses that
had been demonstrated to be compelling in mortality trials. At present, we can't bolster
the standard utilization of high doses of ACE inhibitors as being more successful than the
objective doses recorded.
16
Garg and Yusuf, “Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on
Mortality and Morbidity in Patients with Heart Failure. Collaborative Group on ACE Inhibitor Trials.”
17
“ACE Inhibitors | Johns Hopkins Diabetes Guide.”
18
Packer Milton et al., “Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme
Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure.”

May 1, 2020
10
(19
)
b) BETA BLOCKERS (BB)s
Beta-blocker treatment is demonstrated in all patients with systolic HF aside from those
with dyspnea very still, the individuals who can't endure beta blockers and the individuals
who are hemodynamically unstable. Albeit beta blockers must be regulated carefully to
patients with HF, essential consideration doctors can endorse them securely. The
underlying measurement ought to be multiplied each two to about a month until the
patient can't endure more elevated levels or the objective dose is reached. Patients who
create hypotension, side effects of hypotension, expanding dyspnea or declining heart
function ought to be assessed. It might be important to expand the diuretic
measurements, decline the beta-blocker dose or cease the beta blocker. (20
)(21
)(22
)
Beta blockers should possibly be included when patients are clinically steady. The
motivation behind beta-blocker treatment is to slow the movement of the ailment. Beta
blockers are not to be included as salvage tranquilizes in patients who are
decompensating.
19
Herman et al., “[Figure, Dicarboxyl-Containing ACE Inhibitors and Doses. Contributed by Linda L
Herman].”
20
Packer et al., “The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure.
U.S. Carvedilol Heart Failure Study Group.”
21
“Effect of Metoprolol CR/XL in Chronic Heart Failure.”
22
“The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II).”

May 1, 2020
11
Most patients with known asymptomatic left ventricular failure, have likewise had a
myocardial dead tissue. The advantages of beta blockers in such patients have been all
around depicted, and these specialists ought to be administered. (23
) Numerous different
patients in this gathering may have hypertension or different signs for beta-blocker
treatment. No practically identical information are accessible on asymptomatic patients
with idiopathic HF.
Some vulnerability despite everything exists about the wellbeing and viability of beta
blockers in patients with dyspnea very still. Two huge preliminaries—the Carvedilol
Prospective Randomized Cumulative Survival (COPERNICUS) trial and the Beta Blocker
Evaluation Survival Trial (BEST)—were intended to address this issue. The information
wellbeing checking board halted the COPERNICUS preliminary early on account of critical
enhancements in mortality.15 Over-all, carvedilol diminished mortality by 35 percent over
fake treatment. In any case, these information have not yet been distributed, and some
debate exists concerning the rejection standards utilized in understanding choice. Patients
who had plain volume over-burden and patients who as of late required intravenous
inotropic operators were among the individuals who were avoided from the COPERNICUS
preliminary. (24
)
BEST was halted ahead of schedule without showing of a critical mortality benefit. The
consequences of this investigation likewise stay unpublished, and data is accessible just
from early information discharges. The BEST examination explored the beta blocker
bucindolol, and a few analysts accept that the consequences of the preliminary might be
explicit to this medication. Racial contrasts were likewise found in BEST, and it is indistinct
whether the high number of dark patients, whose results were the most exceedingly awful
in the preliminary, may have influenced the general result. Additionally, it is conceivable
that the negative outcome originated from the incorporation of a generally high number
of patients with dyspnea very still. (25
)
Beta blockers ought not be given if their utilization is completely contraindicated in view of
conditions, for example, bradycardia, heart or serious bronchospastic illness. Diabetes and
asthma ought not be viewed as total contraindications to the utilization of these
23
“A Randomized Trial of Propranolol in Patients with Acute Myocardial Infarction. I. Mortality Results.”
24
Fowler, “Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial.”
25
Beta-Blocker Evaluation of Survival Trial Investigators et al., “A Trial of the Beta-Blocker Bucindolol in
Patients with Advanced Chronic Heart Failure.”

May 1, 2020
12
medications. Patients with these comorbid conditions ought to be given a preliminary of
beta blockers.
(26
)
c) SPIRONOLACTONE
Spironolactone is a potassium-saving diuretic and an aldosterone adversary. The
Randomized Aldactone Survival Study (RALES)(27
) as of late exhibited that aldosterone
26
“Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There
Room for Improvement? - ScienceDirect.”

May 1, 2020
13
antagonism with spironolactone brings down mortality and hospitalization rates in
patients with systolic failure who have dyspnea very still or a background marked by
dyspnea very still inside the previous a half year. Hyperkalemia was uncommon
(occurrence: 0.5 percent), despite the fact that patients were additionally accepting ACE
inhibitors. Asymptomatic gynecomastia was likewise moderately phenomenal (7 percent)
when the medication was given in a normal measurements of 25 mg every day. Patients
with HF, dyspnea very still (current or later) and no critical renal dysfunction (serum
creatinine level of under 2.5 mg per dL [221 mmol per L]), ought to be treated with
spironolactone in a dose of 25 mg day by day.
To limit the chance of hyperkalemia, essential consideration doctors ought to be
perceptive of the hazard factors for this issue, which incorporate diminished renal capacity,
potassium supplementation and the utilization of ACE inhibitors or adrenergic receptor
blockers. As a diuretic, spironolactone may likewise influence liquid parity, which ought to
be checked.
A few specialists accept that spironolactone additionally might be helpful in patients with
less serious HF and in those with diastolic dysfunction. In any case, no enormous scope
clinical preliminaries have tended to the wellbeing or viability of spironolactone treatment
in these patients.
d) DIURETICS
Albeit no enormous, controlled clinical investigations have been led on the utilization of
diuretics in the treatment of cardiovascular breakdown, these medications have been given
to most patients as a major aspect of gauge treatment in preliminaries of ACE inhibitors,
beta blockers, spironolactone (Aldactone) and digoxin (Lanoxin).
Loop diuretics are the most strong operators in the diuretic class, yet they are related with
intense and interminable distal loop of Henle. Joining a loop diuretic with a thiazide
diuretic builds diuretic strength by limiting distal function losses. Both loop and thiazide
diuretics produce urinary potassium and magnesium losses.
27
“The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure.
Randomized Aldactone Evaluation Study Investigators. - PubMed - NCBI.”

May 1, 2020
14
Diuretics ought to be utilized varying to treat volume over-burden. Diuretic treatment
might be required intensely and incessantly. (28
)(29
)
(30
)
e) DIGOXIN
Digoxin is shown in the treatment of patients with HF who likewise have atrial fibrillation. It
is additionally shown to improve side effects and abatement hospitalization rates in
patients with suggestive cardiovascular HF. The fitting measurement is 0.25 mg every day;
the dose can be balanced varying, in light of side effects, different medications or renal
impedance. (31
)
Digoxin has been appeared to affect side effects and hospitalization rates, yet not on
mortality. The quantity of medications that beneficially affect mortality in HF is growing.
28
Islam, “The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical
Settings.”
29
Mullens et al., “The Use of Diuretics in Heart Failure with Congestion - a Position Statement from the
Heart Failure Association of the European Society of Cardiology.”
30
“Diuretic Therapy In Heart Failure.”
31
Chavey et al., “Guideline for the Management of Heart Failure Caused by Systolic Dysfunction.”

May 1, 2020
15
(32
) Since taking an expanding number of meds can turn into an obstruction to
consistence, the job that digoxin will eventually play in the treatment of HF is muddled.
At present, the utilization of digoxin in patients who are indicative regardless of treatment
with diuretics, ACE inhibitors and beta blockers and treatment for patients with dyspnea
very still or an ongoing history of dyspnea very still.
(ii) Pharmacologic Therapy: Secondary Drugs
Medications at times utilized in patients with cardiovascular breakdown however not
explicitly suggested for use in this setting are alluded to as "optional medications" in this
rule.
a) DIRECT-ACTING VASODILATORS
In blend, the immediate acting vasodilators isosorbide dinitrate (Isordil) and
hydralazine (Apresoline) were the principal prescriptions appeared to improve
endurance in heart failure. (33
) Subsequently, randomized, controlled preliminaries
showed that ACE inhibitors were better than these agents. (34
) Guidelines from the
Agency for Health Care Policy and Research demonstrate that immediate acting
vasodilators can be viewed as a potential other option if ACE inhibitors are
ineffectively endured in patients with HF. (35
) The clinical preliminaries proposes
that Afro-American races may have more prominent profit by isosorbide dinitrate
and hydralazine than nonblacks. (36
)
32
Digitalis Investigation Group, “The Effect of Digoxin on Mortality and Morbidity in Patients with Heart
Failure.”
33
Cohn et al., “Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a
Veterans Administration Cooperative Study.”
34
Konstam et al., “Heart Failure.”
35
Cohn et al., “A Comparison of Enalapril with Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic
Congestive Heart Failure.”
36
Carson et al., “Racial Differences in Response to Therapy for Heart Failure.”

May 1, 2020
16
(37
)
b) CALCIUM CHANNEL BLOCKERS
Calcium channels blockers have no immediate job in the treatment of HF
coming about because of systolic failure. The original operators diltiazem and
nifedipine were appeared to have unfavorable results in patients with systolic
failure who had a myocardial infarction.(38
)(39
) The dihydropyridine calcium
channel blockers (i.e., amlodipine and felodipine) in patients with New York
Heart Association (NYHA) III/IV manifestations recommended that the
medications were protected however didn't show their viability. (40
)(41
)
Amlodipine proposed a mortality advantage in patients with nonischemic HF.
Presently, no proof backings the utilization of calcium direct blockers in
patients with HF. (42
)
37
“Table 9 – Intravenous Vasodilators Used to Treat Acute Heart Failure.”
38
Multicenter Diltiazem Postinfarction Trial Research Group, “The Effect of Diltiazem on Mortality and
Reinfarction after Myocardial Infarction.”
39
Goldbourt et al., “Early Administration of Nifedipine in Suspected Acute Myocardial Infarction. The
Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study.”
40
Packer et al., “Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure.
Prospective Randomized Amlodipine Survival Evaluation Study Group.”
41
Littler and Sheridan, “Placebo Controlled Trial of Felodipine in Patients with Mild to Moderate Heart
Failure. UK Study Group.”
42
“Prospective Randomized Amlodipine Survival Evaluation 2.”

May 1, 2020
17
(43
)
c) INOTROPES
Intravenous inotropic treatment with the sympathomimetics (dobutamine
[Dobutrex] or dopamine [Intropin]) or the phosphodiesterase inhibitors
(milrinone [Primacor] or amrinone [Inocor]) is held for use in patients
hospitalized for intensely decompensated HF who don't react sufficiently or in
an auspicious way to diuretic treatment, in spite of the fact that mortality
information are lacking. Inotropic operators may increment heart yield and
lessening fundamental and pneumonic vascular obstruction. Discontinuous
bolus treatment or nonstop treatment with dobutamine or milrinone isn't as of
now demonstrated for the routine HF. (44
)
43
“Pharmacotherapy Principles and Practice, Second Edition (Chisholm-Burns, Pharmacotherapy), 2nd Ed.”
44
“Rationale and Design of the OPTIME CHF Trial: Outcomes of a Prospective Trial of Intravenous Milrinone
for Exacerbations of Chronic Heart Failure. - PubMed - NCBI.”

May 1, 2020
18
(45
)
d) ANTICOAGULANTS
Anticoagulation treatment is shown in patients with HF who are in danger for
thromboembolism. Remembered for this gathering are patients with atrial
fibrillation, showed left ventricular thrombus or a background marked by
45
“Management of Atrial Fibrillation in Patients With Structural Heart Disease | Circulation.”

May 1, 2020
19
embolic stroke with the probable source being an expanded left ventricle.
(46
)(47
)
Anticoagulation treatment has likewise been recommended for patients with a
low risk stratification part or an intracardiac thrombus. Be that as it may,
information supporting the utilization of anticoagulant drugs for this sign are
restricted and dubious. Most of studies didn't right for the nearness of
entrenched hazard factors for thrombus development and didn't control for the
degree of anticoagulation or the commencement of anticoagulation. On the off
chance that anticoagulation is required, the proper portion of warfarin
(Coumadin) is dictated by the patient's International Normalized Ratio (INR).
The objective INR will rely upon the clinical condition requiring treatment.
e) ANGIOTENSIN RECEPTOR BLOCKERS (ARB’s)
Angiotensin receptor blockers are safe however have never been demonstrated
to be more effective than ACE inhibitors in mortality preliminaries of patients
with HF. The utilization of angiotensin receptor blockers just in patients who
face side effects with the usage of ACE inhibitors like cough. Indeed, even in
this setting, ARB’s must be utilized with alert in patients who are likewise taking
beta blockers. (48
)(49
)
f) ANTIARRHYTHMIC DRUGS
Proof is conflicting in regards to the advantage of antiarrhythmic treatment in
patients with heart failure. At this time, it doesn't give the idea that
considerable advantage is gotten from the utilization of antiarrhythmic
treatment in patients who have HF and an asymptomatic unsettling influence.
46
Baker and Wright, “Management of Heart Failure. IV. Anticoagulation for Patients with Heart Failure Due
to Left Ventricular Systolic Dysfunction.”
47
Cleland, Torabi, and Khan, “Epidemiology and Management of Heart Failure and Left Ventricular Systolic
Dysfunction in the Aftermath of a Myocardial Infarction.”
48
Pitt et al., “Effect of Losartan Compared with Captopril on Mortality in Patients with Symptomatic Heart
Failure.”
49
Pitt et al., “Randomised Trial of Losartan versus Captopril in Patients over 65 with Heart Failure (Evaluation
of Losartan in the Elderly Study, ELITE).”

May 1, 2020
20
Arrhythmias, for example, atrial fibrillation, ventricular tachycardia and
bradyarrhythmias are basic in patients with cardiovascular changes. In this way,
individualized administration is suggested. Some every now and again utilized
antiarrhythmics, including calcium channel blockers, beta blockers and digoxin,
are tended to in different segments of this article. Amiodarone (Cordarone), a
typical antiarrhythmic, has various medication communications that ought to
be noted. (50
)(51
)
(52
)
(iii) Nonpharmacologic Treatment
a) EXERCISE
Numerous little and here and there randomized clinical preliminaries have inspected
the advantages of activity preparing in patients with heart failure. Different exercises
have been tried in peope, for example, ventilatory limit, most extreme oxygen
50
Singh et al., “Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular
Arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.”
51
Doval et al., “Randomised Trial of Low-Dose Amiodarone in Severe Congestive Heart Failure. Grupo de
Estudio de La Sobrevida En La Insuficiencia Cardiaca En Argentina (GESICA).”
52
“Management of Atrial Fibrillation in Patients With Structural Heart Disease | Circulation.”

May 1, 2020
21
utilization, skeletal muscle parameters and neurohormonal levels; a couple have
estimated practice limit and personal satisfaction.
Up 'til now, be that as it may, no major randomized, controlled preliminary has shown
an improvement in clinical results, for example, medicine decrease, diminished
emergency clinic days or mortality. (53
)
b) DIETARY CHANGES
We are unconscious of any controlled clinical preliminaries of salt or liquid limitation in
the treatment of cardiovascular breakdown. Notwithstanding, dietary sodium limitation
may diminish the requirement for diuretics in patients with clog. The most normally
suggested limit is 2,000 mg of sodium every day. Limiting liquid admission to 2 L or
less every day might be helpful in patients with hyponatremia.
(iv) Devices and Heart Transplant
In individuals with extreme cardiomyopathy (LVEF underneath 35%), or in those with
intermittent VT or dangerous arrhythmias, treatment with a implantable cardioverter
defibrillator (AICD) is demonstrated to diminish the danger of serious hazardous
arrhythmias. (54
)
The AICD doesn't improve side effects or decrease the rate of threatening arrhythmias
however reduces mortality from those arrhythmias, regularly related to antiarrhythmic
meds. In individuals with left ventricular launch (LVEF) underneath 35%, the rate of
ventricular tachycardia (VT) or unexpected heart demise is sufficiently high to warrant
AICD arrangement. Its utilization is in this way suggested in AHA/ACC guidelines. (55
)
Cardiovascular contractility adjustment (CCM) is a treatment for individuals with
moderate to serious left ventricular systolic HF (NYHA class II–IV) which upgrades both
the quality of ventricular compression and the cardiac pumping limit. The CCM
53
McKelvie et al., “Effects of Exercise Training in Patients with Congestive Heart Failure.”
54
Tracy et al., “2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of
Cardiac Rhythm Abnormalities.”
55
Kuck et al., “New Devices in Heart Failure.”

May 1, 2020
22
instrument depends on incitement of the cardiovascular muscle by non-excitatory
electrical signs (NES), which are conveyed by a pacemaker-like gadget. (56
)(57
)
CCM is especially reasonable for the treatment of cardiovascular breakdown with
typical QRS complex length (120 ms or less) and has been shown to improve the side
effects, personal satisfaction and exercise tolerance. CCM is endorsed for use in
Europe, however not at present in North America. (58
)
Around 33% of individuals with LVEF underneath 35% have extraordinarily modified
conduction to the ventricles, coming about in dyssynchronous depolarization of the
privilege and left ventricles. This is particularly hazardous in individuals with left branch
(blockage of one of the two essential leading fiber packages that start at the base of
the heart and conveys depolarizing driving forces to one side ventricle). Utilizing a
unique pacing calculation, biventricular cardiovascular resynchronization treatment
(CRT) can start a typical arrangement of ventricular depolarization. In individuals with
LVEF underneath 35% and delayed QRS term on ECG (LBBB or QRS of 150 ms or more)
there is an improvement in side effects and mortality when CRT is added to standard
clinical therapy. However, in the 66% of individuals without delayed QRS length, CRT
may really be harmful. (59
)
Individuals with the most serious cardiovascular breakdown might be possibility for
ventricular assist devices (VAD). VADs have generally been utilized as an extension to
heart transplantation, yet have been utilized all the more as of late as a goal treatment
for cutting edge heart failure. (60
)
In select cases, heart transplantation can be thought of. While this may resolve the
issues related with cardiovascular breakdown, the individual should by and large stay
on an immunosuppressive routine to forestall dismissal, which has its own critical
downsides. A significant constraint of this treatment choice is the shortage of hearts
accessible for transplantation. (61
)
56
Abraham and Smith, “Devices in the Management of Advanced, Chronic Heart Failure.”
57
Borggrefe and Burkhoff, “Clinical Effects of Cardiac Contractility Modulation (CCM) as a Treatment for
Chronic Heart Failure.”
58
Kuschyk et al., “Efficacy and Survival in Patients with Cardiac Contractility Modulation.”
59
“Cardiac Resynchronization Therapy | Johns Hopkins Medicine.”
60
Carrel et al., “Continuous Flow Left Ventricular Assist Devices.”
61
Lindenfeld et al., “Drug Therapy in the Heart Transplant Recipient.”

May 1, 2020
23
(v) Recommended Algorithms
a) NYHA classification of HF:
(62
)
62
“Classes of Heart Failure | American Heart Association.”

May 1, 2020
24
b) HFrEF Pharmacological Treatment by Canadian cardiovascular Society
(63
)
63
“7.1.1 HFrEF Pharmacological Treatment.”

May 1, 2020
25
c) 2013 ACCF/AHA Guideline for the Management of Heart Failure:
(64
)
64
WRITING COMMITTEE MEMBERS et al., “2016 ACC/AHA/HFSA Focused Update on New Pharmacological
Therapy for Heart Failure.”

May 1, 2020
26
d) NICE guidelines for management of Chronic HF:
(65
)
65
“Overview | Chronic Heart Failure in Adults: Diagnosis and Management | Guidance | NICE.”

May 1, 2020
27
4. Conclusion
Contrast to HF care 20 to 30 years back, there has been gigantic progression in treatment for
mobile HF with decreased ejection fraction with the utilization of drugs that block maladaptive
neurohormonal pathways. Be that as it may, during the previous decade, with scarcely any
eminent special cases, the recurrence of fruitful medication advancement programs has fallen as
most novel treatments have neglected to offer steady profit or raised wellbeing concerns ( i.e.,
hypotension). Also, no treatment has been affirmed explicitly for HF with safeguarded launch
portion or for compounding ceaseless HF (counting intensely decompensated HF). Over the range
of HF, fundamental outcomes from many stage management have been promising yet are
oftentimes trailed by ineffective investigations, featuring a distinction in the translational
procedure between essential science disclosure, early medication improvement, and complete
clinical testing in significant outcomes. A significant neglected need in HF medicate advancement
is the capacity to recognize homogeneous subsets of patients whose hidden ailment is driven by a
particular instrument that can be focused on utilizing another helpful operator. Medication
improvement techniques ought to progressively consider treatments that encourage switch
renovating by straightforwardly focusing on the heart itself as opposed to carefully concentrating
on specialists that target fundamental neurohormones which affect the cardiac capacity.
Headways in cardiovascular imaging may take into consideration increasingly engaged and direct
appraisal of medication impacts on HF from the get-go in the medication improvement process.
To all the more likely comprehend and address the variety of difficulties confronting flow HF
medicate improvement, with the goal that future endeavors may have a superior possibility for
progress.

May 1, 2020
28
5. References:
1. “Dorlands Medical Dictionary:Heart Failure,” May 11, 2009.
https://web.archive.org/web/20090511054808/http://www.mercksource.com/pp/us
/cns/cnss_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/four/00
0047501.htm.
2. Mayo Clinic. “Heart Failure - Symptoms and Causes.” Accessed May 2, 2020.
https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-
causes/syc-20373142.
3. MedicineNet. “Definition of Heart Failure.” Accessed May 2, 2020.
https://www.medicinenet.com/script/main/art.asp?articlekey=3672.
4. “Management of Acute Decompensated Heart Failure - Google Books.” Accessed
May 2, 2020.
https://books.google.ge/books?id=b5oB0Dyoj1IC&pg=PA572&redir_esc=y#v=one
page&q&f=false.
5. “Oxford Textbook of Heart Failure - Roy S. Gardner, Andrew L. Clark, Henry Dargie -
Google Books.” Accessed May 2, 2020.
https://books.google.ge/books?id=r8wowXxC1voC&lpg=PP1&redir_esc=y.
6. “Exercise‐basedCardiacRehabilitation for Adults with Heart Failure.” Accessed May
2, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492482/.
7. National Clinical Guideline Centre (UK). Chronic Heart Failure: National Clinical
Guideline for Diagnosis and Management in Primary and Secondary Care: Partial
Update. National Institute for Health and Clinical Excellence: Guidance. London:
Royal College of Physicians (UK), 2010.
http://www.ncbi.nlm.nih.gov/books/NBK65340/.

May 1, 2020
29
8. WRITING COMMITTEE MEMBERS, Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt,
Javed Butler, Donald E. Casey, Monica M. Colvin, et al. “2016 ACC/AHA/HFSA
Focused Update on New Pharmacological Therapy for Heart Failure: An Update of
the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of
the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines and the Heart Failure Society of America.” Circulation
134, no. 13 (27 2016): e282-293. https://doi.org/10.1161/CIR.0000000000000435.
9. Tracy, Cynthia M., Andrew E. Epstein, Dawood Darbar, John P. DiMarco, Sandra B.
Dunbar, N. A. Mark Estes, T. Bruce Ferguson, et al. “2012 ACCF/AHA/HRS Focused
Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm
Abnormalities: A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the
Heart Rhythm Society. [Corrected].” Circulation 126, no. 14 (October 2, 2012): 1784–
1800. https://doi.org/10.1161/CIR.0b013e3182618569.
10. Kuck, Karl-Heinz, Pierre Bordachar, Martin Borggrefe, Giuseppe Boriani, Haran Burri,
Francisco Leyva, Patrick Schauerte, et al. “New Devices in Heart Failure: An
European Heart Rhythm Association Report: Developed by the European Heart
Rhythm Association; Endorsed by the Heart Failure Association.” Europace:
European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the
Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular
Electrophysiology of the European Society of Cardiology 16, no. 1 (January 2014):
109–28. https://doi.org/10.1093/europace/eut311.
11. Dickstein, Kenneth, Alain Cohen-Solal, Gerasimos Filippatos, John J. V. McMurray,
Piotr Ponikowski, Philip Alexander Poole-Wilson, Anna Strömberg, et al. “ESC
Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2008 of the European Society of Cardiology. Developed in Collaboration
with the Heart Failure Association of the ESC (HFA) and Endorsed by the European
Society of Intensive Care Medicine (ESICM).” European Heart Journal 29, no. 19
(October 2008): 2388–2442. https://doi.org/10.1093/eurheartj/ehn309.
12. Metra, Marco, and John R. Teerlink. “Heart Failure.” Lancet (London, England) 390,
no. 10106 (October 28, 2017): 1981–95. https://doi.org/10.1016/S0140-
6736(17)31071-I.
13. Trevor, Anthony J., Bertram G. Katzung, and Marieke Kruidering-Hall. “Drugs Used
in Heart Failure.” In Katzung & Trevor’s Pharmacology: Examination & Board Review,
11th ed. New York, NY: McGraw-Hill Education, 2015.
accessmedicine.mhmedical.com/content.aspx?aid=1123460047.

May 1, 2020
30
16. Garg, R., and S. Yusuf. “Overview of Randomized Trials of Angiotensin-Converting
Enzyme Inhibitors on Mortality and Morbidity in Patients with Heart Failure.
Collaborative Group on ACE Inhibitor Trials.” JAMA 273, no. 18 (May 10, 1995):
1450–56.
17. “ACE Inhibitors | Johns Hopkins Diabetes Guide.” Accessed May 2, 2020.
https://www.hopkinsguides.com/hopkins/.//view/Johns_Hopkins_Diabetes_Guide/5
47002/all/ACE_inhibitors?refer=true.
18. Packer Milton, Poole-Wilson Philip A., Armstrong Paul W., Cleland John G. F.,
Horowitz John D., Massie Barry M., Rydén Lars, Thygesen Kristian, and Uretsky Barry
F. “Comparative Effects of Low and High Doses of the Angiotensin-Converting
Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure.”
Circulation 100, no. 23 (December 7, 1999): 2312–18.
https://doi.org/10.1161/01.CIR.100.23.2312.
19. Herman, Linda L., Sandeep A. Padala, Pavan Annamaraju, and Khalid Bashir.
“[Figure, Dicarboxyl-Containing ACE Inhibitors and Doses. Contributed by Linda L
Herman].” Text. StatPearls Publishing, April 7, 2020.
https://www.ncbi.nlm.nih.gov/books/NBK431051/figure/article-17584.image.f1/.
20. Packer, M., M. R. Bristow, J. N. Cohn, W. S. Colucci, M. B. Fowler, E. M. Gilbert, and
N. H. Shusterman. “The Effect of Carvedilol on Morbidity and Mortality in Patients
with Chronic Heart Failure. U.S. Carvedilol Heart Failure Study Group.” The New
England Journal of Medicine 334, no. 21 (May 23, 1996): 1349–55.
https://doi.org/10.1056/NEJM199605233342101.
21. “Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL
Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).” Lancet
(London, England) 353, no. 9169 (June 12, 1999): 2001–7.
22. “The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial.” Lancet
(London, England) 353, no. 9146 (January 2, 1999): 9–13.

May 1, 2020
31
23. “A Randomized Trial of Propranolol in Patients with Acute Myocardial Infarction. I.
Mortality Results.” JAMA 247, no. 12 (March 26, 1982): 1707–14.
https://doi.org/10.1001/jama.1982.03320370021023.
24. Fowler, Michael B. “Carvedilol Prospective Randomized Cumulative Survival
(COPERNICUS) Trial: Carvedilol in Severe Heart Failure.” The American Journal of
Cardiology 93, no. 9A (May 6, 2004): 35B-9B.
https://doi.org/10.1016/j.amjcard.2004.01.004.
25. Beta-Blocker Evaluation of Survival Trial Investigators, Eric J. Eichhorn, Michael J.
Domanski, Heidi Krause-Steinrauf, Michael R. Bristow, and Philip W. Lavori. “A Trial
of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure.”
The New England Journal of Medicine 344, no. 22 (31 2001): 1659–67.
26. “Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There
Room for Improvement? - ScienceDirect.” Accessed May 2, 2020.
https://www.sciencedirect.com/science/article/pii/S0735109717368183.
27. “The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe
Heart Failure. Randomized Aldactone Evaluation Study Investigators. - PubMed -
NCBI.” Accessed May 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/10471456.
28. Islam, Md Shahidul. “The Art and Science of Using Diuretics in the Treatment of
Heart Failure in Diverse Clinical Settings.” Advances in Experimental Medicine and
Biology 1067 (2018): 47–65. https://doi.org/10.1007/5584_2018_182.
29. Mullens, Wilfried, Kevin Damman, Veli-Pekka Harjola, Alexandre Mebazaa, Hans-
Peter Brunner-La Rocca, Pieter Martens, Jeffrey M. Testani, et al. “The Use of
Diuretics in Heart Failure with Congestion - a Position Statement from the Heart
Failure Association of the European Society of Cardiology.” European Journal of
Heart Failure 21, no. 2 (2019): 137–55. https://doi.org/10.1002/ejhf.1369.
30. “Diuretic Therapy In Heart Failure.” Accessed May 2, 2020.
https://www.ecrjournal.com/articles/diuretic-therapy-hf.
31. Chavey, William E., Caroline S. Blaum, Barry E. Bleske, Richard Van Harrison, Sean
Kesterson, and John M. Nicklas. “Guideline for the Management of Heart Failure
Caused by Systolic Dysfunction: Part I. Guideline Development, Etiology and
Diagnosis.” American Family Physician 64, no. 5 (September 1, 2001): 769.
https://www.aafp.org/afp/2001/0901/p769.html.
32. Digitalis Investigation Group. “The Effect of Digoxin on Mortality and Morbidity in
Patients with Heart Failure.” The New England Journal of Medicine 336, no. 8
(February 20, 1997): 525–33. https://doi.org/10.1056/NEJM199702203360801.

May 1, 2020
32
33. Cohn, J. N., D. G. Archibald, S. Ziesche, J. A. Franciosa, W. E. Harston, F. E. Tristani, W.
B. Dunkman, W. Jacobs, G. S. Francis, and K. H. Flohr. “Effect of Vasodilator Therapy
on Mortality in Chronic Congestive Heart Failure. Results of a Veterans
Administration Cooperative Study.” The New England Journal of Medicine 314, no.
24 (June 12, 1986): 1547–52. https://doi.org/10.1056/NEJM198606123142404.
34. Konstam, M. A., K. Dracup, D. W. Baker, M. B. Bottorff, N. H. Brooks, R. A. Dacey, S.
B. Dunbar, A. B. Jackson, M. Jessup, and J. C. Johnson. “Heart Failure: Evaluation and
Care of Patients with Left Ventricular Systolic Dysfunction.” Journal of Cardiac
Failure 1, no. 2 (March 1995): 183–87. https://doi.org/10.1016/1071-
9164(95)90021-7.
35. Cohn, J. N., G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W. B.
Dunkman, H. Loeb, and M. Wong. “A Comparison of Enalapril with Hydralazine-
Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure.” The New
England Journal of Medicine 325, no. 5 (August 1, 1991): 303–10.
36. Carson, P., S. Ziesche, G. Johnson, and J. N. Cohn. “Racial Differences in Response to
Therapy for Heart Failure: Analysis of the Vasodilator-Heart Failure Trials.
Vasodilator-Heart Failure Trial Study Group.” Journal of Cardiac Failure 5, no. 3
(September 1999): 178–87. https://doi.org/10.1016/s1071-9164(99)90001-5.
37. ResearchGate. “Table 9 – Intravenous Vasodilators Used to Treat Acute Heart
Failure.” Accessed May 2, 2020. https://www.researchgate.net/figure/Intravenous-
vasodilators-used-to-treat-acute-heart-failure_tbl1_256689749.
38. Multicenter DiltiazemPostinfarction Trial Research Group. “The Effect of Diltiazem
on Mortality and Reinfarction after Myocardial Infarction.” The New England Journal
of Medicine 319, no. 7 (18 1988): 385–92.
39. Goldbourt, U., S. Behar, H. Reicher-Reiss, M. Zion, L. Mandelzweig, and E. Kaplinsky.
“Early Administration of Nifedipine in Suspected Acute Myocardial Infarction. The
Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study.” Archives of
Internal Medicine 153, no. 3 (February 8, 1993): 345–53.
40. Packer, M., C. M. O’Connor, J. K. Ghali, M. L. Pressler, P. E. Carson, R. N. Belkin, A. B.
Miller, et al. “Effect of Amlodipine on Morbidity and Mortality in Severe Chronic
Heart Failure. Prospective Randomized Amlodipine Survival Evaluation Study
Group.” The New England Journal of Medicine 335, no. 15 (October 10, 1996): 1107–
14. https://doi.org/10.1056/NEJM199610103351504.

May 1, 2020
33
41. Littler, W. A., and D. J. Sheridan. “Placebo Controlled Trial of Felodipine in Patients
with Mild to Moderate Heart Failure. UK Study Group.” British Heart Journal 73, no.
5 (May 1995): 428–33. https://doi.org/10.1136/hrt.73.5.428.
42. American College of Cardiology. “Prospective Randomized Amlodipine Survival
Evaluation 2.” Accessed May 2, 2020. http%3a%2f%2fwww.acc.org%2flatest-in-
cardiology%2fclinical-trials%2f2013%2f07%2f13%2f21%2f31%2fpraise2.
43. “Pharmacotherapy Principles and Practice, Second Edition (Chisholm-Burns,
Pharmacotherapy), 2nd Ed.” Accessed May 2, 2020.
https://doctorlib.info/therapy/pharmacotherapy-principles-practice/.
44. “Rationale and Design of the OPTIME CHF Trial: Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic Heart Failure. - PubMed -
NCBI.” Accessed May 2, 2020. https://www.ncbi.nlm.nih.gov/pubmed/10618557.
45. “Management of Atrial Fibrillation in Patients With Structural Heart Disease |
Circulation.” Accessed May 2, 2020.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.019935.
46. Baker, D. W., and R. F. Wright. “Management of Heart Failure. IV. Anticoagulation
for Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction.” JAMA
272, no. 20 (November 23, 1994): 1614–18.
https://doi.org/10.1001/jama.272.20.1614.
47. Cleland, J. G. F., A. Torabi, and N. K. Khan. “Epidemiology and Management of Heart
Failure and Left Ventricular Systolic Dysfunction in the Aftermath of a Myocardial
Infarction.” Heart 91, no. suppl 2 (2005): ii7–ii13.
48. Pitt, B., R. Segal, F. A. Martinez, G. Meurers, A. J. Cowley, I. Thomas, P. C. Deedwania,
D. E. Ney, D. B. Snavely, and P. I. Chang. “Randomised Trial of Losartan versus
Captopril in Patients over 65 with Heart Failure (Evaluation of Losartan in the
Elderly Study, ELITE).” Lancet (London, England) 349, no. 9054 (March 15, 1997):
747–52. https://doi.org/10.1016/s0140-6736(97)01187-2.
49. Pitt, B., P. A. Poole-Wilson, R. Segal, F. A. Martinez, K. Dickstein, A. J. Camm, M. A.
Konstam, et al. “Effect of Losartan Compared with Captopril on Mortality in Patients
with Symptomatic Heart Failure: Randomised Trial--the Losartan Heart Failure
Survival Study ELITE II.” Lancet (London, England) 355, no. 9215 (May 6, 2000):
1582–87. https://doi.org/10.1016/s0140-6736(00)02213-3.
50. Singh, S. N., R. D. Fletcher, S. G. Fisher, B. N. Singh, H. D. Lewis, P. C. Deedwania, B.
M. Massie, C. Colling, and D. Lazzeri. “Amiodarone in Patients with Congestive
Heart Failure and Asymptomatic Ventricular Arrhythmia. Survival Trial of
Antiarrhythmic Therapy in Congestive Heart Failure.” The New England Journal of
Medicine 333, no. 2 (July 13, 1995): 77–82.
51. Doval, H. C., D. R. Nul, H. O. Grancelli, S. V. Perrone, G. R. Bortman, and R. Curiel.
“Randomised Trial of Low-Dose Amiodarone in Severe Congestive Heart Failure.

May 1, 2020
34
Grupo de Estudio de La Sobrevida En La Insuficiencia Cardiaca En Argentina
(GESICA).” Lancet (London, England) 344, no. 8921 (August 20, 1994): 493–98.
https://doi.org/10.1016/s0140-6736(94)91895-3.
52. “Management of Atrial Fibrillation in Patients With Structural Heart Disease |
Circulation.” Accessed May 2, 2020.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.019935.
53. McKelvie, R. S., K. K. Teo, N. McCartney, D. Humen, T. Montague, and S. Yusuf.
“Effects of Exercise Training in Patients with Congestive Heart Failure: A Critical
Review.” Journal of the American College of Cardiology 25, no. 3 (March 1, 1995):
789–96. https://doi.org/10.1016/0735-1097(94)00428-S.
54. Tracy, Cynthia M., Andrew E. Epstein, Dawood Darbar, John P. DiMarco, Sandra B.
Dunbar, N. A. Mark Estes, T. Bruce Ferguson, et al. “2012 ACCF/AHA/HRS Focused
Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm
Abnormalities: A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the
Heart Rhythm Society. [Corrected].” Circulation 126, no. 14 (October 2, 2012): 1784–
1800. https://doi.org/10.1161/CIR.0b013e3182618569.
55. Kuck, Karl-Heinz, Pierre Bordachar, Martin Borggrefe, Giuseppe Boriani, Haran Burri,
Francisco Leyva, Patrick Schauerte, et al. “New Devices in Heart Failure: An
European Heart Rhythm Association Report: Developed by the European Heart
Rhythm Association; Endorsed by the Heart Failure Association.” Europace:
European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the
Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular
Electrophysiology of the European Society of Cardiology 16, no. 1 (January 2014):
109–28. https://doi.org/10.1093/europace/eut311.
56. Abraham, William T., and Sakima A. Smith. “Devices in the Management of
Advanced, Chronic Heart Failure.” Nature Reviews. Cardiology 10, no. 2 (February
2013): 98–110. https://doi.org/10.1038/nrcardio.2012.178.
57. Borggrefe, Martin, and Daniel Burkhoff. “Clinical Effects of Cardiac Contractility
Modulation (CCM) as a Treatment for Chronic Heart Failure.” European Journal of
Heart Failure 14, no. 7 (July 2012): 703–12. https://doi.org/10.1093/eurjhf/hfs078.
58. Kuschyk, Jürgen, Susanne Roeger, Raphaela Schneider, Florian Streitner, Ksenija
Stach, Boris Rudic, Christel Weiß, et al. “Efficacy and Survival in Patients with Cardiac
Contractility Modulation: Long-Term Single Center Experience in 81 Patients.”
International Journal of Cardiology 183 (March 15, 2015): 76–81.
https://doi.org/10.1016/j.ijcard.2014.12.178.

May 1, 2020
35
59. “Cardiac Resynchronization Therapy | Johns Hopkins Medicine.” Accessed May 2,
2020. https://www.hopkinsmedicine.org/health/treatment-tests-and-
therapies/cardiac-resynchronization-therapy.
60. Carrel, Thierry, Lars Englberger, Michele V. Martinelli, Jukka Takala, Claudia Boesch,
Vilborg Sigurdadottir, Erich Gygax, Alexander Kadner, and Paul Mohacsi.
“Continuous Flow Left Ventricular Assist Devices: A Valid Option for Heart Failure
Patients.” Swiss Medical Weekly 142 (2012): w13701.
https://doi.org/10.4414/smw.2012.13701.
61. Lindenfeld, JoAnn, Geraldine G. Miller, Simon F. Shakar, Ronald Zolty, Brian D.
Lowes, Eugene E. Wolfel, Luisa Mestroni, Robert L. Page, and Jon Kobashigawa.
“Drug Therapy in the Heart Transplant Recipient: Part I: Cardiac Rejection and
Immunosuppressive Drugs.” Circulation 110, no. 24 (December 14, 2004): 3734–40.
https://doi.org/10.1161/01.CIR.0000149745.83186.89.
62. “Classes of Heart Failure | American Heart Association.” Accessed May 2, 2020.
https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-
of-heart-failure.
63. “7.1.1 HFrEF Pharmacological Treatment.” Accessed May 2, 2020.
https://www.ccs.ca/eguidelines/Content/Topics/HeartFailure/711%20HFrEF%20Phar
macological%20Treatment.htm.
64. WRITING COMMITTEE MEMBERS, Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt,
Javed Butler, Donald E. Casey, Monica M. Colvin, et al. “2016 ACC/AHA/HFSA
Focused Update on New Pharmacological Therapy for Heart Failure: An Update of
the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of
the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines and the Heart Failure Society of America.” Circulation
134, no. 13 (27 2016): e282-293. https://doi.org/10.1161/CIR.0000000000000435.
65. “Overview | Chronic Heart Failure in Adults: Diagnosis and Management | Guidance
| NICE.” Accessed May 2, 2020. https://www.nice.org.uk/guidance/ng106.

Cardiology: Treatment of Heart Failure

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Cardiology: Treatment of Heart Failure

Similar to Cardiology: Treatment of Heart Failure (20)

More from Vedica Sethi

More from Vedica Sethi (11)

Recently uploaded

Recently uploaded (20)

Cardiology: Treatment of Heart Failure